Trial Profile
Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- 11 Apr 2012 Actual patient number amended from 26 to 25 and primary endpoint added as reported by ClinicalTrials.gov.
- 14 Dec 2011 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 14 Dec 2011 Actual initiation date changed from Mar 2005 to Jan 2005 as reported by ClinicalTrials.gov.